Cystic Fibrosis Clinical Trial
Official title:
A Multi-Site Randomized Clinical Trial of Behavioral and Nutrition Treatment Designed to Help Preschoolers With Cystic Fibrosis Optimize Growth
The primary objective of this NIH funded clinical trial is to conduct a multi-center, randomized, controlled trial comparing two interventions: a behavioral plus nutrition intervention to a nutrition intervention. This study will (a) determine the impact of the behavioral intervention on energy intake and weight gain; (b) examine the durability of the behavioral intervention's impact on growth (weight and height) one year following treatment; and (c) explore the relation between physical activity and growth.
Evidence-based nutritional interventions that achieve and sustain optimal growth in young
children with cystic fibrosis (CF) do not exist, despite an urgent need. Such an intervention
could positively change the course of clinical lung disease and enhance survival for these
children. The primary objective of this NIH funded clinical trial is to conduct a
multi-center, randomized, controlled trial comparing two interventions: a behavioral plus
nutrition intervention to a nutrition (attention control) intervention. All subjects will
receive nutritional care consistent with the 2001 CF Consensus Conference guidelines for
pediatric nutrition.
The specific aims are to:
1. determine the impact of the behavioral intervention on energy intake and weight gain;
2. examine the durability of the behavioral intervention's impact on growth (weight and
height) one year following treatment; and
3. explore the relation between physical activity and growth. The central hypothesis is
that behavioral intervention will lead to better growth as measured by change in weight
and height for age z scores.
From three CF Centers in Ohio, (Cincinnati Children's, Columbus Children's, Rainbow Babies
and Children's Hospital in Cleveland), two referral centers in Ohio (Dayton Children's and
Akron Children's), one CF Center in Michigan (University of Michigan-Ann Arbor), and one CF
Center in Arizona (University of Arizona-Tucson), 100 preschoolers with CF and pancreatic
insufficiency age 2 to 6 years will be randomized to one of the two conditions. The two
groups will be stratified so that they are similar at the initiation of treatment on weight
for age z score.
Other critical variables such as history of Pseudomonas aeruginosa infection and gender will
be used as covariates in the statistical analysis plan. Outcome data (energy intake measured
by 7-day diet record, weight, height) will be obtained at baseline, post-treatment (6
months), and after a 12-month follow-up (18 months post baseline).
Secondary measures will include body mass index, body composition measured by dual energy
x-ray absorptiometry (DXA) and skinfolds, and growth velocity. Behavioral treatment will
maximize adherence to a high energy diet and enzyme replacement therapy, and motivate
children to increase their energy intake. It involves 7 weekly sessions followed by 4 monthly
sessions. The attention condition controls for time of contact and number of assessments
conducted.
This study advances the investigation of early nutritional interventions for young children
with CF and directly addresses the need for controlled, longitudinal assessment of behavioral
intervention on growth. The long-range goal is to change the standard of nutritional care for
young children with CF because behavioral intervention leads to optimal growth and ultimately
improves lung health and survival.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
| Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
| Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
| Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
| Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
| Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
| Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
| Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
| Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
| Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
| Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
| Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
| Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
| Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
| Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
| Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
| Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
| Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
| Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |